Navigation Links
TriReme Medical Announces Japanese Alliance
Date:1/9/2011

PLEASANTON Calif., SINGAPORE and TOKYO, Jan. 10, 2011 /PRNewswire/ -- TriReme Medical, Inc. (TriReme) today announced that it has signed an exclusive distribution and sales agreement for TriReme's complete line of advanced peripheral and coronary balloon dilatation catheters with Century Medical, Inc. (CMI), a leading independent device distributor for the important Japanese market.

TriReme recently received clearance from the U.S. Food and Drug Administration (FDA) for the GliderXtreme™ PTA balloon catheter, a highly differentiated balloon catheter with an expanded matrix of sizes including longer balloon lengths, an atraumatic tapered tip and shaft construction reinforced for torque transmission and exceptional pushability.  GliderXtreme™ is designed to cross difficult and highly diseased lesions to restore blood flow in the complex peripheral anatomy. TriReme's coronary version of this product, known as the Glider™ PTCA balloon catheter is a state-of-the-art catheter designed to overcome the limitations of conventional balloon catheters in treating complex disease by improving torque and push transmission. The combined PTCA & PTA balloon markets represent more than a $400 million catheter device revenue opportunity in Japan.

"CMI's long and successful history of obtaining timely regulatory approvals , launching new products , building strong dedicated sales and marketing teams and rapidly expanding market share makes it an ideal partner for us in Japan," Dr. Eitan Konstantino, President and CEO of TriReme said. "This agreement is a critical step in the realization of our Asian strategy. We look forward to working with CMI to develop this important market and to move market adoption to TriReme's line of product."

Akira Hoshino, President and CEO of CMI, commented that, "We are very pleased to have entered into this long-term distribution agreement with TriReme.  TriReme has proven itself quite capable of creating advanced, innovative products to fill significant unmet needs in rapidly expanding medical device markets.  We are very impressed with TriReme's catheter products and development capabilities.  We look forward to working closely with TriReme."  

About TriReme Medical, Inc.

Based in Pleasanton, CA and Singapore, TriReme Medical, Inc., is a privately held medical device company dedicated to the development, manufacturing, and commercialization of advanced therapeutic solutions for the treatment of complex vascular disease.  

About Century Medical, Inc.

Based in Tokyo, Japan, Century Medical, Inc. is a $140 million subsidiary company of ITOCHU Corporation (TSE: ITC) a $115 billion international trading company.  Century Medical, Inc., with approx. 300 employees, has a 36 year experience specializing in the importation; sale and marketing of advanced single use and implantable medical devices.


'/>"/>
SOURCE TriReme Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. TriReme Medical Inc. Receives CE Marking for Antares(TM) Coronary Stent System
2. TriReme Medical, Inc. Receives FDA 510K Clearance for Glider(TM) PTA Balloon Catheter
3. TriReme Medical Announces $17 Million Series D Financing
4. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
5. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
6. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
7. Globus Medical Raises $110 Million in Series E Financing Round
8. Quark Pharmaceuticals Appoints New Chief Medical Officer
9. Boston University Biomedical Engineers Find Chink in Bacterias Armor
10. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
11. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... 2017 Nevro Corp. (NYSE: NVRO), a global medical ... treatment of chronic pain, today reported financial results for the ... 2016 Accomplishment & Highlights: Achieved ... increase of 228% as reported, over the prior year ... of 612% over the prior year International ...
(Date:2/23/2017)... Calif. , Feb. 23, 2017 ... company focused on the development and commercialization of ... pain, announced that it will release fourth quarter ... Thursday, March 2nd, 2017. AcelRx management will host ... Time (1:30 p.m. Pacific Time) on March 2 ...
(Date:2/23/2017)... , Feb 23, 2017 ... Research and Markets has announced the ... Industry Forecast to 2025" report to their offering. ... of around 1.8% over the next decade to reach approximately $12.8 billion ... estimates and forecasts for all the given segments on global as well ...
Breaking Medicine Technology:
(Date:2/23/2017)... , ... February 23, 2017 , ... ... of Justice jointly issued a letter to withdraw previous guidance issued ... their gender identity. The guidance issued in May 2016 by the Obama Administration ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... with a clinician-based audience, will be participating in Rare Disease Day events, hosted ... D.C. In addition, Rare Disease Report, a website, weekly e-newsletter and quarterly publication, ...
(Date:2/23/2017)... , ... February 23, 2017 , ... Hamlin Dental Group ... that they are sponsoring a raffle. Throughout the month of February, patients who visit ... a gift card for a dinner for two at the Cheesecake Factory. , ...
(Date:2/23/2017)... Los Angeles, California (PRWEB) , ... February 23, ... ... for Global Sports Development will host a diverse symposium on “Doping ... School of Law and Sheppard Mullin Richter & Hampton LLP. The symposium will ...
(Date:2/23/2017)... ... 23, 2017 , ... ERT, a global data and technology ... Research, a leading clinical development service provider, has selected ERT’s Trial Oversight suite ... in part to an array of circumstances including the use of multiple data ...
Breaking Medicine News(10 mins):